文献速递中医内科中药与中成药合理使用

和胃颗粒预防晚期结直肠癌化疗所致恶心呕吐的前瞻性随机对照试验

Herbal medicine for the prevention of chemotherapy-induced nausea and vomiting in patients with advanced colorectal cancer: A prospective randomized controlled trial.
PubMed 文献 · J Ethnopharmacol · 2024-02-08

本研究为多中心随机对照试验,纳入120例接受氟尿嘧啶类化疗的晚期结直肠癌患者,比较和胃颗粒联合标准止吐方案与安慰剂的疗效。结果显示和胃颗粒在延迟期恶心呕吐的完全缓解率和客观缓解率有显著改善,急性期客观缓解率亦提高,且未发生与中药相关的严重不良事件。

要点

  • 和胃颗粒可改善延迟期化疗所致恶心呕吐的完全缓解率和客观缓解率。
  • 急性期完全缓解率无显著差异,但客观缓解率有提高趋势。
  • 和胃颗粒未增加严重不良事件,耐受性良好。

核心结论

  • 和胃颗粒预防晚期结直肠癌患者化疗所致恶心呕吐有效且耐受性良好,对延迟性CINV获益明显。

研究设计与样本

  • 多中心随机对照试验,2020年10月至2022年2月在中国西南地区12个病房开展。
  • 共纳入120例接受氟尿嘧啶类化疗的晚期结直肠癌患者,按1:1随机分为和胃颗粒组与安慰剂组,112例完成两周期并纳入全分析集(每组56例)。

主要发现

  • 急性期恶心呕吐完全缓解率组间差异无统计学意义(平均差10.7%,P=0.318、0.324),客观缓解率提高约17.5%(平均差16.1%,P=0.051;17.9%,P=0.037)。
  • 延迟期恶心呕吐完全缓解率提高约20%(平均差19.6%,P=0.053;21.4%,P=0.035),客观缓解率提高(平均差17.9%,P=0.037、0.043)。
  • CINV事件每日发生率平均差19%(P<0.05);约70%接受和胃颗粒的患者FLIE评分显示CINV对日常生活无影响。
  • 未发生归因于中药的严重不良事件。

关键数值与推荐

  • 完全缓解率定义为无恶心呕吐的患者比例,客观缓解率定义为无恶心呕吐加上轻度恶心呕吐的患者比例。
  • 急性CINV定义为治疗开始后24小时内发生,延迟性CINV定义为治疗开始后24至120小时发生。

临床怎么用

  • 对于接受氟尿嘧啶类化疗的晚期结直肠癌患者,可考虑在和胃颗粒联合5-HT3受体拮抗剂和地塞米松用于预防CINV,尤其关注延迟期获益。

局限性

  • 本研究为II期探索性试验,样本量有限,结果需进一步III期临床试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Chinese herbal medicine is increasingly used as complementary therapy to manage nausea and vomiting in different cultures. One such herbal recipe is the Hezhong granules, which contain classical antiemetic formulations, and are commonly used to prevent chemotherapy-induced nausea and vomiting (CINV). Modern pharmacological studies have shown that the key components of Hezhong granules, including Pinellia ternata (Thunb.), Evodia rutaecarpa (Juss.), and Zingiber officinale exhibit significant antiemetic and antitumor properties. Despite this promising evidence, controlling CINV remains a significant challenge in cancer treatment. Moreover, there is a lack of scientifically designed clinical trials to validate the efficacy and safety of classical antiemetic formulas for CINV interventions. AIMS OF THE STUDY: To investigate the efficacy and safety of Hezhong granules in preventing CINV in patients with advanced colorectal cancer (CRC). METHODS: This study was conducted between October 2020 and February 2022 in 12 hospital wards in Southwest China. In this multicenter, randomized controlled trial, we enrolled patients with advanced CRC who received fluorouracil-based chemotherapy. The patients were randomly assigned in a 1:1 ratio to either the Hezhong granule group (receiving a 5-HT3-receptor antagonist, dexamethasone, and Hezhong granules) or the placebo group (receiving a 5-HT3-receptor antagonist, dexamethasone, and placebo) during the first and second courses of chemotherapy. A 5-day diary was provided to all patients. Acute and delayed CINV were defined as CINV occurring within 24 h or between 24 and 120 h after the start of treatment. The primary endpoints were complete response rate (CRR, defined as the proportion of patients without nausea/vomiting) and objective response rate (ORR, defined as the proportion of patients without nausea/vomiting plus mild nausea/vomiting) for both acute and delayed CINV. Secondary endpoints were the daily rates of CINV events and Functional Living Index-Emesis (FLIE). To identify the predictors of CINV, we conducted multivariate ordered logistic regression analysis. This study was registered with the Chinese Clinical Trial, number ChiCTR2100041643. RESULTS: A total of 120 participants were randomly assigned, of whom 112 (56/56) completed two cycles and were included in the full analysis. In the acute phase, there were minor improvements in the Hezhong granule group, but there were no significant differences in the CRRs for nausea and vomiting (mean difference:10.7 %, P = 0.318, 0.324), while the ORRs increased by approximately 17.5 % (mean difference:16.1 %, P = 0.051; 17.9 %, P = 0.037, respectively). In the delayed phase, significant improvements of approximately 20 % were observed in both the CRRs (mean difference:19.6 %, P = 0.053; 21.4 %, P = 0.035) and ORRs (mean difference:17.9 %, P = 0.037, 0.043) for nausea and vomiting. Additionally, the daily rate of CINV events showed a mean difference of 19 % (P < 0.05). According to FLIE scores, approximately 70 % of patients who received Hezhong granules reported an improvement in their quality of life, with CINV symptoms having"no impact on daily life (NIDL)". No serious adverse events were attributed to herbal medicine. CONCLUSIONS: Hezhong granules proved to be both effective and well-tolerated in preventing CINV in patients with advanced CRC, with notable benefits in preventing delayed CINV. These promising results set the stage for subsequent phase III clinical trials and experimental research on Hezhong Granules.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Wu Z, Fu X, Jing H, et al. Herbal medicine for the prevention of chemotherapy-induced nausea and vomiting in patients with advanced colorectal cancer: A prospective randomized controlled trial. J Ethnopharmacol. 2024. PMID: 38341113. doi:10.1016/j.jep.2024.117853

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。